The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CLDX | -7.09% | +63.73% | +10.36% | -76% |
| S&P | +15.06% | +95.03% | +14.29% | +429% |
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
The biotech's CSU treatment advanced in the laboratory.
The short answer: They were impressive.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.73M | -70.8% |
| Gross Profit | -$0.14M | -108.4% |
| Gross Margin | -19.59% | -87.7% |
| Market Cap | $1.35B | -44.6% |
| Market Cap / Employee | $7.26M | 0.0% |
| Employees | 186 | 16.3% |
| Net Income | -$56.60M | -57.9% |
| EBITDA | -$62.98M | -38.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $23.04M | -46.1% |
| Accounts Receivable | $0.09M | -94.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.50M | 87.8% |
| Short Term Debt | $1.54M | -3.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.96% | 0.3% |
| Return On Invested Capital | -26.63% | 6.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$44.73M | -51.1% |
| Operating Free Cash Flow | -$44.01M | -50.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.87 | 2.13 | 1.61 | 1.92 | -33.93% |
| Price to Sales | 225.88 | 238.85 | 159.39 | 233.31 | -20.73% |
| Price to Tangible Book Value | 2.97 | 2.21 | 1.67 | 2.00 | -33.51% |
| Enterprise Value to EBITDA | -29.33 | -17.41 | -8.74 | -11.59 | -67.99% |
| Return on Equity | -29.8% | -26.8% | -23.2% | -27.2% | -1.30% |
| Total Debt | $3.09M | $3.81M | $3.43M | $3.03M | 27.09% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
